# Table 1 Arithmetic mean of live tick counts and percent efficacy relative to placebo for dogs treated once orally with Simparica Trio™ at 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt)

Count timeaTreatment groupDayb
0714212835
8 hoursPlacebo18.120.7d21.619.117.717.7
Simparica Trio™5.98.0d17.113.917.116.8
% Efficacy67.561.5d20.627.33.15.0
Test statistict(9.71) = 2.19t(6.99) = 5.18t(40) = 0.84t(12.3) = 1.29t(13.7) = 0.23t(7.68) = 0.75
P-valuec0.05450.00130.40690.21910.81860.4751
12 hoursPlacebo21.323.618.921.2d24.919.6
Simparica Trio™0.33.67.78.0d11.910.9
% Efficacy98.484.959.462.2d52.244.3
Test statistict(13.2) = 18.10t(9.39) = 6.21t(40) = 4.00t(6.6) = 4.32t(13.8) = 1.79t(13.3) = 2.27
P-valuec< 0.00010.00010.00030.00400.09570.0404
24 hoursPlacebo17.417.224.116.823.114.8
Simparica Trio™0.10.10.00.31.34.8
% Efficacy99.499.410098.094.267.7
Test statistict(9.29) = 9.34t(9.04) = 11.33t(40) = 12.89t(9.29) = 7.98t(8.03) = 9.62t(9.12) = 4.22
P-valuec< 0.0001< 0.0001< 0.0001< 0.0001< 0.00010.0022
1. aTime after treatment or subsequent weekly tick infestations
2. bDay of treatment (Day 0) and of subsequent weekly tick infestations
3. cP-value for comparison of arithmetic mean tick counts between Simparica Trio™ and placebo groups at each time point within a row, P ≤ 0.05 indicates significant difference
4. dTime point with missing observations, back-transformed least squares means and corresponding percent efficacy estimates were used